NAMI Pharma Marketing Blog Grassley
View PDF of blog article here
Similar Posts
Intimidation, Politics and Drug Industry Cripple U.S. Medicine – FDA Permits Dr. David Graham to publish Vioxx Report
Intimidation, Politics and Drug Industry Cripple U.S. Medicine – FDA Permits Dr. David Graham to publish Vioxx Report Wed, 5 Jan 2005 FDA officials could not maintain their iron grip in an effort to suppress evidence of far reaching lethal effects of Vioxx when their actions were in full public…
The FDA and Drug Safety: A Proposal for Sweeping Changes
A Special Article By Curt D. Furberg, MD, PhD; Arthur A. Levin, MPH; Peter A. Gross, MD; Robyn S. Shapiro, JD; Brian L. Strom, MD, MPH
Top FDA Officials, Compromised by Conflicts of Interest
Two high ranking FDA officials’ conflicts of interest have led one to resign, the other is under investigation by the Inspector General of the Department of Health and Human Services:
Glaxo Pricing Under DOJ investigation / GAO Report Says Medicaid Overpays for Drugs
Glaxo Pricing Under DOJ investigation / GAO Report Says Medicaid Overpays for Drugs Wed, 9 Mar 2005 Reuters reports that GlaxoSmithKline is under investigation by the Department of Justice concerning Medicaid drug pricing. The skyrocketing cost of drugs is depleting Medicaid, the nation’s largest health insturance program paid for by…
How Did the Vioxx Debacle Happen? USA Today / Lancet
How Did the Vioxx Debacle Happen? USA Today / Lancet Tue, 12 Oct 2004 Dr. Eric Topol of the Cleveland Clinic: “The senior executives at Merck and the leadership at the FDA share responsibility for not having taken appropriate action and not recognizing that they are accountable for the public…
Top SFBC officials Quit Amid Senate Inquiry Clinical Trials_ Bloomberg News
In its continuing coverage of corrupt clinical drug trial practices, Bloomberg News reports that all three founders of SFBC International, one of the largest clinical trial business operations that had failed to even screen human subjects for turberculosis, and threatened others with deportation if they refused to become guinea pigs, quit after the Senate Finance committee began investigating drug trial safety issues: